Comparison
Alpha-Lipoic Acid vs BPC-157
Side-by-side of Alpha-Lipoic Acid and BPC-157. Every row below is pulled from the compound schema and will update as our data grows. For deeper reads, follow through to each compound page.
Alpha-Lipoic Acid
Alpha lipoic acid supplement guide: 600 mg/day oral dosing, R-ALA vs racemic absorption, neuropathy trial data, antioxidant mechanism, interactions.
BPC-157
BPC-157 peptide profile: pentadecapeptide body protection compound 157. Preclinical data on tendon, gut healing, recovery. No human RCTs as of 2026.
Effects at a glance
Alpha-Lipoic Acid
- •Approved Rx for diabetic neuropathy in Germany at 600 mg/day IV (Thioctacid) since 1960s
- •Improves neuropathy symptoms (TSS, NIS) at 600 mg/day IV across ALADIN and SYDNEY trials
- •R-ALA enantiomer absorbs 40-100% better than racemic mixtures
- •Activates AMPK; produces small HbA1c reductions in T2DM
- •Plasma half-life ~30 minutes; split dosing or sustained-release is standard
- •Hypoglycemia risk with insulin or sulfonylureas; medication adjustment may be required
BPC-157
- •Preclinical models show accelerated tendon-to-bone and ligament healing after surgical or chemical injury
- •Rodent studies report mucosal protection and faster recovery from NSAID-induced and colitis-induced gut damage
- •Anecdotal human protocols use 250 to 500 mcg twice daily subcutaneously near the injury site
- •No completed phase II or III human RCTs as of 2026, so efficacy and long-term safety remain unestablished
- •Banned by WADA since 2022 under the S0 non-approved substances category for competitive athletes
- •Theoretical angiogenic concern means avoidance is prudent in active malignancy until human data exists
Side-by-side
| Attribute | Alpha-Lipoic Acid | BPC-157 |
|---|---|---|
| Category | supplement | peptide |
| Also known as | ALA, thioctic acid, R-ALA, R-lipoic acid | Body Protection Compound-157, Pentadecapeptide BPC-157 |
| Half-life (hr) ↗ | 0.5 | 4 |
| Typical dose (mg) ↗ | 600 | 0.25 |
| Dosing frequency | 1 to 3 times daily on empty stomach | daily (anecdotal protocols) |
| Routes | oral, iv | subcutaneous, intramuscular, oral |
| Onset (hr) | 0.5 | - |
| Peak (hr) | 1 | - |
| Molecular weight | 206.33 | - |
| Molecular formula | C8H14O2S2 | C62H98N16O22 |
| Mechanism | Dual lipid- and water-soluble antioxidant; redox cycles with dihydrolipoic acid (DHLA) to scavenge ROS, regenerate vitamin E and C, and chelate transition metals. Activates AMPK in liver and muscle; cofactor for pyruvate and alpha-ketoglutarate dehydrogenase complexes. | Proposed upregulation of VEGFR2 and nitric oxide pathways, modulation of growth-hormone receptor expression, and stabilization of gut-brain axis signaling. Mechanism remains largely preclinical. |
| Legal status | Dietary supplement (US, UK, Canada, most EU); prescription drug for diabetic neuropathy in Germany | Not FDA approved; research-use-only grey market; banned by WADA (2022) |
| WADA status | allowed | banned |
| DEA / Rx | Not scheduled | Not FDA approved; not scheduled; research-chemical status |
| Pregnancy | Insufficient data; precautionary avoidance | Insufficient data |
| CAS | 62-46-4 | 137525-51-0 |
| PubChem CID | 864 | 9941957 |
| Wikidata | Q161227 | Q4835418 |
Safety profile
Alpha-Lipoic Acid
Common side effects
- nausea
- abdominal discomfort
- diarrhea
- sulfurous odor
- rash (rare)
Contraindications
- pregnancy and lactation (insufficient safety data)
- active insulin autoimmune syndrome predisposition
Interactions
- insulin and sulfonylureas: additive hypoglycemia; medication dose adjustment may be required(major)
- thyroid hormone: may reduce T4 to T3 conversion at high doses(moderate)
- biotin: ALA competes with biotin uptake; chronic use can induce biotin insufficiency(minor)
- iron supplements: ALA chelates iron and reduces absorption; separate dosing(moderate)
- chemotherapy (oxidative-stress-dependent agents): theoretical interference; coordinate with oncology team(moderate)
BPC-157
Common side effects
- injection-site irritation
- nausea
- headache (anecdotal)
Contraindications
- pregnancy
- active malignancy (theoretical angiogenic concern)
- no established safety profile in humans
Which Should You Take?
Alpha-Lipoic Acid comes out ahead for most readers on the criteria we weight: 3 catalogued goals, OTC dietary supplement, oral dosing, with a Tier-B outcome catalogued. BPC-157 is the right call when one of the conditionals below applies.
- → If your priority is metabolic health and glucose control, pick Alpha-Lipoic Acid.
- → If your priority is healthspan extension, pick Alpha-Lipoic Acid.
- → If your priority is post-training recovery, pick BPC-157.
- → If your priority is gut barrier and microbiome health, pick BPC-157.
Edge case: If you want to avoid research-only / gray-market sourcing, Alpha-Lipoic Acid is the more accessible choice.
Default choice: Alpha-Lipoic Acid. Lower friction to source, and broader goal coverage. Reach for BPC-157 only if your priority sits squarely in the goals it owns above.
This verdict is generated from each compound's schema (goals, legal status, evidence outcomes, dosing route). It updates automatically as our compound data evolves; the deeper read sits on each individual compound page.
Common questions
What is the difference between Alpha-Lipoic Acid and BPC-157?
Alpha-Lipoic Acid and BPC-157 differ in category (supplement vs peptide), mechanism, and typical dosing. See the side-by-side table for full details.
Which has a longer half-life, Alpha-Lipoic Acid or BPC-157?
Alpha-Lipoic Acid half-life is 0.5 hours; BPC-157 half-life is 4 hours.
Can you stack Alpha-Lipoic Acid with BPC-157?
Stack compatibility depends on mechanism overlap, legal status, and individual response. Check each compound page for specific interactions and contraindications before combining.
Go deeper